Current/ Expected Orderbook/ Pending Orders?

Some backlog orders from the previous quarter due to shipping and supply chain issues (notably Red Sea disruptions) were cleared and reflected in the current quarter's revenue. However, some backlog still remains and has been incorporated into ongoing planning. The current quarter itself has created new backlog, which will carry over into the next quarter. Improved planning has helped address shipment delays to a large extent, stabilizing order fulfillment. Overall, the backlog situation is being actively managed but is not completely resolved yet, awaiting improvement in global shipping condi

Any current/future new fundraising through debt or equity?

Glenmark Life Sciences does not plan to raise debt for expansion; all expansion will be funded through internal accruals. The company aims to remain debt-free, with no requirement for leveraging the balance sheet at this stage. There was no mention of any immediate or future equity fundraising in the transcript. Current capex plans for FY '25 are between INR 300-350 crores, funded internally. The company may retain some cash on the balance sheet due to high capex commitment, leading to moderate dividend payout, but not specifying any fundraising through equity.

Any current/future capex/capital investment/strategic investment?

Current year (FY'25) capex planned between INR 300 crores to INR 340 crores. Major investment toward building greenfield site at Solapur, expected completion in about 18-20 months; total Solapur capex around INR 350-400 crores. Addition of new pharma capacity at Ankleshwar and Dahej plants (e.g., pharma modules in Q2 and Q4 FY'25). Investing in new R&D center to support expansion into new technology platforms and portfolio avenues with backing from Nirma. Capex to meet environmental regulations continues, including commissioning of third Effluent Treatment Plant (ETP) next month; any additiona

Future growth expectations in sales/revenue/volumes?

FY '25 started positively with close to 10% sequential revenue growth, indicating a strong and resilient business. Broad-based growth witnessed across geographies including India, Japan, and Rest of the World. Medium-term growth outlook remains unchanged with expectations of mid- to high-teens growth for the external business. Brownfield expansions have provided a runway of about 1.5 years to cater to additional demand. New greenfield Solapur facility under construction, expected to be completed in 18 to 20 months, will further boost capacity. CDMO segment expected to pick up from Q3 FY '25, w

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Life Sciences started FY '25 on a positive note with close to 10% sequential growth, indicating a strong and resilient business. The demand outlook is good, with growth expected to continue across regions over the next couple of quarters. The medium-term growth outlook remains unchanged with additional capacity coming online (e.g., Solapur Phase I to complete in 18-20 months). EBITDA margins are stable at around 28%, with expectations to maintain or improve margins from current levels. Gross margins have faced pressure due to product mix and the discontinuation of PLI benefits

Alivus Life Sciences LtdQ1 FY25Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,268.6P/E: 25.0Market Cap: ₹15.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

FY '25 started positively with close to 10% sequential revenue growth, indicating a strong and resilient business.
Broad-based growth witnessed across geographies including India, Japan, and Rest of the World.
Medium-term growth outlook remains unchanged with expectations of mid- to high-teens growth for the external business.
Brownfield expansions have provided a runway of about 1.5 years to cater to additional demand.
New greenfield Solapur facility under construction, expected to be completed in 18 to 20 months, will further boost capacity.
CDMO segment expected to pick up from Q3 FY '25, with additional projects in the pipeline and steady momentum.
Pipeline continuously being filled, with 5 new products added recently; 20 high-potency APIs targeting a $4 billion market.
Demand outlook is improving with increasing momentum in specialty and innovator segments.

Margin guidance

Category 3

Glenmark Life Sciences started FY '25 on a positive note with close to 10% sequential growth, indicating a strong and resilient business.
The demand outlook is good, with growth expected to continue across regions over the next couple of quarters.
The medium-term growth outlook remains unchanged with additional capacity coming online (e.g., Solapur Phase I to complete in 18-20 months).
EBITDA margins are stable at around 28%, with expectations to maintain or improve margins from current levels.
Gross margins have faced pressure due to product mix and the discontinuation of PLI benefits but are not expected to decline further.
Free cash flow generation is strong, supporting capex and potentially steady dividend payout, although dividend growth payout may moderate.
Continued investment in capacity expansion (INR300-350 crores capex in FY '25) supports future revenue growth.
Overall, stable margins with mid-to-high teens growth in external business revenues are anticipated.

See what Alivus Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Glenmark Life Sciences does not plan to raise debt for expansion; all expansion will be funded through internal accruals.
The company aims to remain debt-free, with no requirement for leveraging the balance sheet at this stage.
There was no mention of any immediate or future equity fundraising in the transcript.
Current capex plans for FY '25 are between INR 300-350 crores, funded internally.
The company may retain some cash on the balance sheet due to high capex commitment, leading to moderate dividend payout, but not specifying any fundraising through equity.

Order book

Yes

Some backlog orders from the previous quarter due to shipping and supply chain issues (notably Red Sea disruptions) were cleared and reflected in the current quarter's revenue.
However, some backlog still remains and has been incorporated into ongoing planning.
The current quarter itself has created new backlog, which will carry over into the next quarter.
Improved planning has helped address shipment delays to a large extent, stabilizing order fulfillment.
Overall, the backlog situation is being actively managed but is not completely resolved yet, awaiting improvement in global shipping conditions.

See what Alivus Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current year (FY'25) capex planned between INR 300 crores to INR 340 crores.
Major investment toward building greenfield site at Solapur, expected completion in about 18-20 months; total Solapur capex around INR 350-400 crores.
Addition of new pharma capacity at Ankleshwar and Dahej plants (e.g., pharma modules in Q2 and Q4 FY'25).
Investing in new R&D center to support expansion into new technology platforms and portfolio avenues with backing from Nirma.
Capex to meet environmental regulations continues, including commissioning of third Effluent Treatment Plant (ETP) next month; any additional environmental capex expected to be marginal.
Capex investment will be calibrated to align with demand, product mix, and regulatory approvals without overinvestment.
Expansion funded through internal accruals; no new debt planned.
Strategic focus on building specialty and CDMO business segments.

Track Alivus Life Sciences Ltd — get its next earnings analysis in your feed

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlivus Life Sciences Ltd

Rev 3Mar 3

See where Alivus Life Sciences Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alivus Life Sciences Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Himalaya Nutravedics (Q2 FY27)
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). Key investor prese
Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alivus Life Sciences Ltd Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alivus Life Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alivus Life Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season